Results 121 to 130 of about 11,732 (171)

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]

Cancer Manag Res
Maeda K, Kawada K, Hayashi T, Koyama S, Ishida T, Yoshioka T, Fukuda H, Horikawa I, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Ishizawa K.   +13 more
europepmc   +1 more source

Limited benefits of neoadjuvant therapy on R0 resection rate and overall survival in patients with resectable or locally advanced PDAC in randomized controlled trials. [PDF]

Front Med (Lausanne)
Liang H, Wu YK.
europepmc   +1 more source

Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial'. [PDF]

ESMO Open
Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D.   +19 more
europepmc   +1 more source

The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. [PDF]

Support Care Cancer
Strijk GJ, van Diepen AE, Wilmink JW, Rietjens JAC, Haberkorn BCM, Stiggelbout AM, Homs MYV, de Vos-Geelen J, van Eijck CHJ, van Eijck CWF.   +9 more
europepmc   +1 more source

Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. [PDF]

J Natl Cancer Inst
Verkolf EMM, van Dam JL, Dekker EN, Janssen QP, Prakash LR, DeSilva A, de Wilde RF, Besselink MG, Wei AC, Zureikat AH, Katz MHG, Tzeng CD, Groot Koerkamp B, Trans-Atlantic Pancreatic Surgery (TAPS) Consortium .   +13 more
europepmc   +1 more source

Massive bleeding from a Bricker ileal conduit during FOLFIRINOX therapy in noncirrhotic portal hypertension: suspected oxaliplatin-associated sinusoidal injury and presumed irinotecan-associated conduit mucositis: a case report. [PDF]

BMC Urol
Drobot RB, Ślósarz T, Antoniewicz AA.
europepmc   +1 more source

Longitudinal assessment of health-related quality of life in patients with borderline and locally advanced pancreatic cancer undergoing neoadjuvant FOLFIRINOX chemotherapy: results from a prospective multicenter trial. [PDF]

Langenbecks Arch Surg
de Carvalho LFA, Ceelen W, Meertens A, Rashidian N, Waked B, Geboes K, Ribeiro S, Gorleer K, Dedecker H, Triest L, Vervaecke A, Sas S, Sierens B, Beyls C, Sie M, van Dijk M, Verhaeghe N, Berrevoet F.   +17 more
europepmc   +1 more source

The Differential Impact of Neoadjuvant Therapies on the Tumor Microenvironment, Peripheral Biomarkers, and Survival in Pancreatic Cancer: A Retrospective Cohort Study. [PDF]

Cancers (Basel)
Silva T, Yamazaki T, Creasy JM, Gerry JM, Zheng-Lin B, Srivastava AJ, Young KH.   +6 more
europepmc   +1 more source

Pre-Emptive Amlodipine for FOLFIRINOX-Induced Hypertensive Crises Without Primary Hypertension: A Novel Chronotherapeutic Strategy. [PDF]

Clin Case Rep
Pustake M, Wells-Gatnik W, Shukla V, Corral J, Gaur S.   +4 more
europepmc   +1 more source

Real-world outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel and prognostic factors in advanced pancreatic cancer: a retrospective cohort study. [PDF]

Ther Adv Med Oncol
Escriva-Aranda C, Giner-Moreno E, Soria Hernández E, Esteve Gallego J, Gómez Roch E, Capdevila P, Carrasco Picazo C, Ortiz Gracia A, Vidal Jiménez D, Aparicio J, Díaz Beveridge R.   +10 more
europepmc   +1 more source